Scholarlink

<p>In recent years, numerous studies have investigated the use of poly (ADP-ribose) polymerase (PARP) inhibitors, labelled with various radionuclides, as agents for targeted radionuclide therapy. This review discusses current advances in studies with radiolabelled PARP inhibitors for targeted radionuclide therapy, focusing on radionuclide selection and (radio)biological properties. We highlight differences between radionuclides and their efficacy in killing cancer cells, while safeguarding healthy tissue. Furthermore, important biomarkers and dosimetry are explored, providing insights and future directions for advancing radiolabelled PARP inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Ahmad Kurniawan,
  • Luis Hernandez Cano,
  • Nerea Delgado Mayenco,
  • Sreelakshmi Unnikrishnan,
  • Philip H. Elsinga,
  • Inês F. Antunes,
  • Erik F.J. de Vries,
  • Bart Cornelissen

摘要

In recent years, numerous studies have investigated the use of poly (ADP-ribose) polymerase (PARP) inhibitors, labelled with various radionuclides, as agents for targeted radionuclide therapy. This review discusses current advances in studies with radiolabelled PARP inhibitors for targeted radionuclide therapy, focusing on radionuclide selection and (radio)biological properties. We highlight differences between radionuclides and their efficacy in killing cancer cells, while safeguarding healthy tissue. Furthermore, important biomarkers and dosimetry are explored, providing insights and future directions for advancing radiolabelled PARP inhibitors.